Trending:
News
-
19 October 2018
ACCC’s appeal over Pfizer Australia ruling on Lipitor dismissed
The Australian high court has dismissed the Australian Competition and Consumer Commission's (ACCC) application for special leave to appeal the Pfizer Australian ruling by the full federal court decision that...
-
19 October 2018
Deals this week: Eisai Pharmaceutical, Abbvie, Otsuka
Eisai Pharmaceutical has signed an agreement with Eurofarma Laboratorios for the marketing and distribution of its anti-obesity drug lorcaserin hydrochloride (marketed as BELVIQ in the US) in 17 countries in...
-
19 October 2018
Deals this week: Emergent BioSolutions, Pediapharm, Adynxx
Emergent BioSolutions has acquired Adapt Pharma in a deal valued at up to $735m.
-
19 October 2018
Novartis to acquire US cancer drug developer Endocyte for $2.1bn
Swiss pharmaceutical firm Novartis has signed a $2.1bn deal to purchase all outstanding shares of US-based biopharmaceutical company Endocyte in order to bolster its position in radiopharmaceuticals.
-
19 October 2018
Takeda gets Japanese approval for $62bn Shire acquisition
Takeda Pharmaceutical is close to completing the $62bn acquisition of Irish biopharmaceutical company Shire after receiving approval from the Japan Fair Trade Commission
-
18 October 2018
Changsheng Bio-Technology fined $1.3bn after vaccine scandals
A Chinese drug watchdog has imposed a fine and asset seizure worth CNY9.1bn ($1.3bn) on Changsheng Bio-Technology following two major vaccine scandals.
-
18 October 2018
Sanofi’s Dupixent meets Phase III trial endpoints for rhinosinusitis
Sanofi has reported positive results from two Phase III clinical trials for its Dupixent drug in adults with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
-
17 October 2018
Samsung Bioepis’ biosimilar to Humira launched in the EU
Samsung Bioepis has announced the launch of its Imraldi, an adalimumab biosimilar to Humira, in the European Union (EU); the drug will be available immediately on the UK’s National Health...
-
17 October 2018
SQZ Biotech signs up to $1bn immuno-oncology deal with Roche
Cell therapy company SQZ Biotechnologies has expanded its deal worth up to $1bn with Roche for the development and commercialisation of immune-oncology products.
-
17 October 2018
Samsung BioLogics may face legal action for alleged accounting breach
South Korea-based biopharmaceutical company Samsung BioLogics is likely to face disciplinary measures due to alleged accounting breach.
